timothy sykes logo

Stock News

Moderna Eyes Higher Revenue and Strategic Approvals at J.P. Morgan Event

Tim SykesAvatar
Written by Timothy Sykes Reviewed by Jack Kellogg Fact-checked by Ellis Hobbs
Updated 1/13/2026, 5:04 pm ET 1/13/2026, 5:04 pm ET | 4 min 4 min read
Moderna Eyes Higher Revenue and Strategic Approvals at J.P. Morgan Event Thumbnail

Moderna Inc. stocks have been trading up by 16.9 percent as promising data boosts investors’ optimism.

Candlestick Chart

Live Update At 17:03:48 EST: On Tuesday, January 13, 2026 Moderna Inc. stock [NASDAQ: MRNA] is trending up by 16.9%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

In recent earnings highlights, the company reported revenues of $3.24B for the year. Revenue growth is aimed at 10% by 2026 following improved sales figures and reduced operating costs. MRNA’s gross margin stood at 48.1%, while net income posted a noticeable drop, attributed, in part, to escalating R&D expenses—an indication of the investment in innovation.

The balance sheet remains robust, evidenced by a current ratio of 3.9, suggesting strong liquidity coverage. Moderna had total assets worth $12.14B, juxtaposed with total liabilities of $2.8B, emphasizing financial soundness. Achieving this financial balance involved strategic investment in PPE and emphasizing non-current assets.

On the market, the stock recently closed at $39.6, witnessing fluctuations over the past month. Improved sell-side projections further indicate investor confidence, highlighting a gradual post-earnings uptick. Analysts give a mean price target of $35.74, suggesting a conservative hold outlook.

Market Expansion and Challenges

The company’s agenda emphasizes regulatory submissions for its influenza vaccine, supported by positive data demonstrating efficacy and safety. The company’s pipeline is a testament to their strategic intent to diversify offerings beyond COVID-19 vaccines. Acceptance from regulatory bodies would not only represent approval but also market validation, paving a path to lucrative segments they are targeting.

Moderna’s results from Phase 3 testing of the product mRNA-1010 demonstrate superior efficacy, empowering the biopharma company to approach regulatory bodies in multiple markets, spanning the U.S., EU, Canada, and Australia. The move is indicative of confidence in scientific output and respective market strategies. Further, the company expects regulatory nods on combination vaccines as well, promising innovation in flu and COVID prophylaxis.

An ongoing legal battle with Monsanto over protected RNA technology presents headwinds. Such legal challenges might induce investor caution as it’s a frontier paving way for new technological advancements yet simultaneously bringing about potential setbacks.

More Breaking News

Conclusion

Moderna’s strategic maneuvers foreshadow a promising yet challenging path. With heightened focus on targeted product approvals and anticipatory investments, the company projects fortifying its financial standing while navigating legal turmoils. As millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.” This serves as a reminder that fluttering trader sentiment is likely, as approval outcomes and resolutions or expansions on legal fronts unfold. Cautious traders eye the stock as a potential value proposition amidst changing dynamics, understanding the importance of patience and strategic decision-making.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Tim Sykes

Head Writer at TimothySykes.com, Lead Mentor at the Trading Challenge
In his 20-plus years of trading, Tim has made $7.9 million. In his 15-plus years of teaching, Tim’s Trading Challenge has produced over 30 millionaire students. His philosophy emphasizes small gains and cutting losses quickly.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”